GSK’s Greener Inhaler Trial Reaches Completion: What Investors Should Watch

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study.

The study, officially titled “A Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Long-term Safety of Salbutamol Rescue Medication When Administered Via Metered Dose Inhalers Containing the Propellant HFA-152a or Reference HFA-134a,” compares two inhaler propellants in adults with asthma. It aims to show that a lower-impact propellant can deliver rescue treatment safely, which matters for both patient care and future inhaler regulations.

The trial tests salbutamol, a common asthma rescue medicine, delivered via two metered dose inhalers that differ only in propellant. One arm uses HFA-152a, a newer, lower global-warming propellant, while the other uses the established HFA-134a. The goal is to see if the new option keeps safety and tolerability on par with the current standard.

This is an interventional Phase 3 study with randomized allocation to one of two treatment arms. It uses a parallel-group design with quadruple blinding, meaning patients, doctors, trial staff, and outcome assessors do not know which inhaler is used, and the main purpose is to test treatment safety over three months of regular rescue use.

The study was first submitted on 2024-02-08, anchoring the timeline for regulatory and disclosure tracking. It is now listed as completed, with the last update filed on 2026-02-24, signaling that fresh information has been reviewed and the dataset is moving toward public results and possible label or portfolio decisions.

For investors, a positive safety readout for HFA-152a could support GSK’s inhaler franchise as payers and regulators push for greener devices. Strong data would likely improve confidence in GSK’s ability to defend and refresh its respiratory portfolio against peers such as AstraZeneca and Boehringer Ingelheim, while any safety concerns could weigh on sentiment and delay a transition to low-impact propellants.

While top-line numbers are not yet posted, the completion and recent update of this trial suggest GSK is on track with its climate-conscious inhaler strategy and may soon communicate more detail to the market. The study is completed and recently updated, with further details available on the ClinicalTrials portal.

To learn more about GSK’s potential, visit the GlaxoSmithKline drug pipeline page.